Inclusion in the world health organization model list of essential medicines of non-vitamin k anticoagulants for treatment of non-valvular atrial fibrillation: A step towards reducing the burden of cardiovascular morbidity and mortality

Ezequiel J. Zaidel; Xinyi Leng; Abiodun Moshood Adeoye; Ferdous Hakim; Biraj Karmacharya; Asim Katbeh; Lis Neubeck; Stephanie Partridge; Pablo Perel; Mark D. Huffman; Mariachiara Di Cesare

doi:10.5334/GH.608

Inclusion in the world health organization model list of essential medicines of non-vitamin k anticoagulants for treatment of non-valvular atrial fibrillation: A step towards reducing the burden of cardiovascular morbidity and mortality

Ezequiel J. Zaidel^*, Xinyi Leng, Abiodun Moshood Adeoye, Ferdous Hakim, Biraj Karmacharya, Asim Katbeh, Lis Neubeck, Stephanie Partridge, Pablo Perel, Mark D. Huffman, Mariachiara Di Cesare^*

^*Corresponding author for this work

Preventive Medicine

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in the treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the world recommending NOACs over vitamin K antagonist oral anticoagulants for initial treatment of AF for stroke prevention. Here we describe the evidence collated and the process followed for the successful inclusion of NOACs into the 21st WHO Model List of Essential Medicines (EML). Individual NOACs have been reported to be non-inferior or superior to warfarin in preventing stroke and systemic embolism in eligible AF patients with a reduction in the risk of stroke and systemic embolism and a lower risk of major bleeding in patients with non-valvular AF compared with warfarin in both RCTs and real-world data. The successful inclusion of NOACs in the WHO EML is an important step forward in the global fight against cardiovascular morbidity and mortality, especially in low- and middle-income countries, where the burden of disease is high and limited access to diagnosis and treatment translates into a higher burden of morbidity, mortality, and economic costs.

Original language	English (US)
Article number	52
Journal	Global heart
Volume	15
Issue number	1
DOIs	https://doi.org/10.5334/GH.608
State	Published - Aug 2020

Funding

MDH has received support from the American Heart Association, Verily, and AstraZeneca for work unrelated to this research. MDH has received salary support from the American Medical Association for his role as an associate editor for JAMA Cardiology. The George Institute for Global Health has a patent and license and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. LN received speakers fees from Daiichi Sankyo unrelated to this research. EJZ received speakers fees from Novartis, Pfizer and Bayer unrelated to this research. The author alone is responsible for the views expressed in this article, which do not necessarily represent the views, decisions or policies of the institution.

Keywords

Essential Medicine List
Non-valvular atrial fibrillation
Non-vitamin K antagonist oral anticoagulants (NOACs)
Prevention
Stroke

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Community and Home Care
Epidemiology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5334/GH.608

Fingerprint

Dive into the research topics of 'Inclusion in the world health organization model list of essential medicines of non-vitamin k anticoagulants for treatment of non-valvular atrial fibrillation: A step towards reducing the burden of cardiovascular morbidity and mortality'. Together they form a unique fingerprint.

Cite this

Zaidel, E. J., Leng, X., Adeoye, A. M., Hakim, F., Karmacharya, B., Katbeh, A., Neubeck, L., Partridge, S., Perel, P., Huffman, M. D., & Di Cesare, M. (2020). Inclusion in the world health organization model list of essential medicines of non-vitamin k anticoagulants for treatment of non-valvular atrial fibrillation: A step towards reducing the burden of cardiovascular morbidity and mortality. Global heart, 15(1), Article 52. https://doi.org/10.5334/GH.608

@article{94b802afe21e4d35b19800425bfd5b7c,

title = "Inclusion in the world health organization model list of essential medicines of non-vitamin k anticoagulants for treatment of non-valvular atrial fibrillation: A step towards reducing the burden of cardiovascular morbidity and mortality",

abstract = "Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in the treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the world recommending NOACs over vitamin K antagonist oral anticoagulants for initial treatment of AF for stroke prevention. Here we describe the evidence collated and the process followed for the successful inclusion of NOACs into the 21st WHO Model List of Essential Medicines (EML). Individual NOACs have been reported to be non-inferior or superior to warfarin in preventing stroke and systemic embolism in eligible AF patients with a reduction in the risk of stroke and systemic embolism and a lower risk of major bleeding in patients with non-valvular AF compared with warfarin in both RCTs and real-world data. The successful inclusion of NOACs in the WHO EML is an important step forward in the global fight against cardiovascular morbidity and mortality, especially in low- and middle-income countries, where the burden of disease is high and limited access to diagnosis and treatment translates into a higher burden of morbidity, mortality, and economic costs.",

keywords = "Essential Medicine List, Non-valvular atrial fibrillation, Non-vitamin K antagonist oral anticoagulants (NOACs), Prevention, Stroke",

author = "Zaidel, {Ezequiel J.} and Xinyi Leng and Adeoye, {Abiodun Moshood} and Ferdous Hakim and Biraj Karmacharya and Asim Katbeh and Lis Neubeck and Stephanie Partridge and Pablo Perel and Huffman, {Mark D.} and {Di Cesare}, Mariachiara",

year = "2020",

month = aug,

doi = "10.5334/GH.608",

language = "English (US)",

volume = "15",

journal = "Global heart",

issn = "2211-8160",

publisher = "Elsevier Science & Technology",

number = "1",

}

Zaidel, EJ, Leng, X, Adeoye, AM, Hakim, F, Karmacharya, B, Katbeh, A, Neubeck, L, Partridge, S, Perel, P, Huffman, MD & Di Cesare, M 2020, 'Inclusion in the world health organization model list of essential medicines of non-vitamin k anticoagulants for treatment of non-valvular atrial fibrillation: A step towards reducing the burden of cardiovascular morbidity and mortality', Global heart, vol. 15, no. 1, 52. https://doi.org/10.5334/GH.608

Inclusion in the world health organization model list of essential medicines of non-vitamin k anticoagulants for treatment of non-valvular atrial fibrillation: A step towards reducing the burden of cardiovascular morbidity and mortality. / Zaidel, Ezequiel J.; Leng, Xinyi; Adeoye, Abiodun Moshood et al.
In: Global heart, Vol. 15, No. 1, 52, 08.2020.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Inclusion in the world health organization model list of essential medicines of non-vitamin k anticoagulants for treatment of non-valvular atrial fibrillation

T2 - A step towards reducing the burden of cardiovascular morbidity and mortality

AU - Zaidel, Ezequiel J.

AU - Leng, Xinyi

AU - Adeoye, Abiodun Moshood

AU - Hakim, Ferdous

AU - Karmacharya, Biraj

AU - Katbeh, Asim

AU - Neubeck, Lis

AU - Partridge, Stephanie

AU - Perel, Pablo

AU - Huffman, Mark D.

AU - Di Cesare, Mariachiara

PY - 2020/8

Y1 - 2020/8

N2 - Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in the treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the world recommending NOACs over vitamin K antagonist oral anticoagulants for initial treatment of AF for stroke prevention. Here we describe the evidence collated and the process followed for the successful inclusion of NOACs into the 21st WHO Model List of Essential Medicines (EML). Individual NOACs have been reported to be non-inferior or superior to warfarin in preventing stroke and systemic embolism in eligible AF patients with a reduction in the risk of stroke and systemic embolism and a lower risk of major bleeding in patients with non-valvular AF compared with warfarin in both RCTs and real-world data. The successful inclusion of NOACs in the WHO EML is an important step forward in the global fight against cardiovascular morbidity and mortality, especially in low- and middle-income countries, where the burden of disease is high and limited access to diagnosis and treatment translates into a higher burden of morbidity, mortality, and economic costs.

AB - Non-vitamin K antagonist oral anticoagulants (NOACs) represent a paradigm shift in the treatment of non-valvular atrial fibrillation (AF) with major practice guidelines around the world recommending NOACs over vitamin K antagonist oral anticoagulants for initial treatment of AF for stroke prevention. Here we describe the evidence collated and the process followed for the successful inclusion of NOACs into the 21st WHO Model List of Essential Medicines (EML). Individual NOACs have been reported to be non-inferior or superior to warfarin in preventing stroke and systemic embolism in eligible AF patients with a reduction in the risk of stroke and systemic embolism and a lower risk of major bleeding in patients with non-valvular AF compared with warfarin in both RCTs and real-world data. The successful inclusion of NOACs in the WHO EML is an important step forward in the global fight against cardiovascular morbidity and mortality, especially in low- and middle-income countries, where the burden of disease is high and limited access to diagnosis and treatment translates into a higher burden of morbidity, mortality, and economic costs.

KW - Essential Medicine List

KW - Non-valvular atrial fibrillation

KW - Non-vitamin K antagonist oral anticoagulants (NOACs)

KW - Prevention

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85090361206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090361206&partnerID=8YFLogxK

U2 - 10.5334/GH.608

DO - 10.5334/GH.608

M3 - Article

C2 - 32923346

AN - SCOPUS:85090361206

SN - 2211-8160

VL - 15

JO - Global heart

JF - Global heart

IS - 1

M1 - 52

ER -

Inclusion in the world health organization model list of essential medicines of non-vitamin k anticoagulants for treatment of non-valvular atrial fibrillation: A step towards reducing the burden of cardiovascular morbidity and mortality

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this